Recent developments in tuberculosis vaccines
- 1 June 2005
- journal article
- review article
- Published by Wolters Kluwer Health in Current Opinion in Infectious Diseases
- Vol. 18 (3) , 211-215
Abstract
The aim is to review findings related to the use of Bacille Calmette-Guérin (BCG) vaccine, focusing on its limitations and benefits in controlling tuberculosis (TB). Some new TB vaccines, which have entered or are expected to enter clinical trials, are highlighted. BCG is currently the only available vaccine against TB, and is widely administered within the World Health Organization Expanded Programme for Immunization. Several trials have shown that the protective efficacy of BCG varies between different populations. Recently, a 60-year follow-up study of American Indians reported the long-term efficacy of BCG to be 52%. The reasons for the low efficacy of the BCG vaccine may be generic differences in the BCG strains, differences in immunological properties of study populations or exposure to environmental factors such as mycobacteria. The low efficacy of the BCG vaccine has encouraged the search for a new vaccine. Among new vaccine candidates are live attenuated Mycobacterium tuberculosis vaccines, recombinant BCG, DNA vaccines, subunit vaccines and fusion proteins with novel adjuvants and delivery systems. Today, most of the world's population is vaccinated with BCG. It is generally accepted that BCG protects against childhood TB but this immunity wanes with age, resulting in no or insufficient protection against TB. Using modern techniques, several research groups have developed more than 200 new vaccine candidates. Some of these vaccines are now in clinical trials. The clinical evaluation of these new vaccines should be designed to cover a heterogeneous population with great variation in immune responses.Keywords
This publication has 47 references indexed in Scilit:
- A Heterologous DNA Priming- Mycobacterium bovis BCG Boosting Immunization Strategy Using Mycobacterial Hsp70, Hsp65, and Apa Antigens Improves Protection against Tuberculosis in MiceInfection and Immunity, 2004
- Cellular immune responses induced in cattle by heterologous prime–boost vaccination using recombinant viruses and bacille Calmette–GuérinImmunology, 2004
- A single vaccination with protein-microspheres elicits a strong CD8 T-cell-mediated immune response against Mycobacterium tuberculosis antigen Mtb8.4Vaccine, 2004
- Recombinant BCG exporting ESAT-6 confers enhanced protection against tuberculosisNature Medicine, 2003
- Dendritic cells recruited to the lung shortly after intranasal delivery of Mycobacterium bovis BCG drive the primary immune response towards a type 1 cytokine productionImmunology, 2003
- Oral Vaccination with Subunit Vaccines Protects Animals against Aerosol Infection withMycobacterium tuberculosisInfection and Immunity, 2002
- Live antigen carriers as tools for improved anti-tuberculosis vaccinesFEMS Immunology & Medical Microbiology, 1999
- The BCG Story: Lessons from the Past and Implications for the FutureClinical Infectious Diseases, 1989
- The effect of two distinct forms of cell-mediated response to mycobacteria on the protective efficacy of BCGTubercle, 1981
- Efficacy and applicability of mass B. C.G. vaccination in tuberculosis control.BMJ, 1967